Pembrolizumab plus radiation for resected mucosal melanoma
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial studies whether giving pembrolizumab (an immunotherapy) together with a targeted form of radiation can help after surgery for mucosal melanoma. It aims to lower the chance of the cancer coming back and improve outcomes in people whose tumor was removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mucosal melanoma confirmed by tissue or cell testing, and it was removed with surgery.
- You must not have had radiation in the same treatment area before.
- You’re age 16 or older, and you’re well enough to do daily activities (performance status 0–2).
- Your blood counts and organ tests (kidneys, liver) need to be within allowed ranges.
- If you can become pregnant (or you’re a man who could have a partner who can become pregnant), you must use reliable birth control during the study and for 6 months after the last dose.
- You can sign consent and understand the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests giving radiation and immunotherapy before surgery for mucosal melanoma in the nose/sinuses or rectum. It may help shrink the tumor and improve outcomes while aiming to control the disease locally and in nearby areas.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a combination of carilizumab (an immunotherapy drug) and apatinib (a targeted therapy) with radiation therapy for people with advanced mucosal melanoma that has come back or spread. The goal is to see if this triple approach can shrink tumors and help patients live longer.
This trial tests whether giving pembrolizumab (an immunotherapy medicine) together with short-course radiation before surgery helps people with localized rectal cancer. It is mainly for tumors that are microsatellite stable (MSS).
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
This Phase 3 trial studies whether adding pembrolizumab (an immune medicine) to focused radiation (SABR) can better control head and neck cancer that has spread to only 1–5 spots. It may help some people live longer or delay cancer worsening by treating both the immune system and the specific metastases.
Hear when a new Mucosal Melanoma of the Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.